Latest News

In February 2026, rusfertide garnered priority review, ASH published new guidelines, and luspatercept mets its primary endpoint in a phase 2a trial.

Isaacs and Bellini discuss recent updates on Eli Lilly's orforglipron and retatrutide and Novo Nordisk's UBT251, along with other recent GLP-1 news.

New research links dietary protein, ammonia buildup, and liver cancer growth, raising questions about targeted nutrition in HCC risk management.

Catch up with FDA decisions, key trial results, and more.

Parent company United Therapeutics announced ralinepag’s substantial reduction in worsening clinical events, as well as improving 6MWD and NT-proBNP.

Risankizumab achieved superiority for the co-primary and ranked secondary endpoints at week 12 for SC injection versus placebo.

The FDA granted Priority Review and accepted a New Drug Application for rusfertide to treat adults with polycythemia vera.

A new study stratified patients by longitudinal BEC patterns to assess whether variability in eosinophil levels influences response.

Navepegritide, to be marketed as YUVIWEL, is the only FDA-approved treatment providing continuous CNP exposure over its weekly dosing interval.

These new data from the OLYMPIA open-label extension study highlight long-term safety and efficacy findings on nemolizumab (Nemluvio).

Ross Milner, MD, discusses rising vascular complexity, advanced imaging and AI, and the team-based strategies driving durable aortic and limb salvage outcomes.

Panelist member explains new ASH guidelines aim to improve early diagnosis of AL amyloidosis with blood, urine, and biopsy testing.

Manreet Kanwar, MD, outlines advances in heart failure care, rising medication complexity, and the need for integrated, patient-centered systems.

AAAAI 2026 showcases high-impact clinical trials and innovative sessions, 5 of which are highlighted below.

David Rubin, MD, discusses rapid advances in IBD care, new therapies, multidisciplinary models, and the push toward precision GI medicine.

Parent company Eli Lilly has released full data from ACHIEVE-3, indicating superior weight loss and A1C reductions with orforglipron 12 mg and 36 mg.

The supplemental New Drug Application submission comes as a result of positive phase 3 data from the CORE and CORE2 trials or olezarsen in 2025.

Claims study suggests dry powder and soft mist COPD inhalers cut exacerbations versus MDIs, offering greener care without added safety risks.

The FDA has approved proprietary desmopressin oral solution formulation ET-600 for the treatment of central diabetes insipidus in children.

Vanda Pharmaceuticals announced the FDA's acceptance of imsidolimab's Biologics License Application for the treatment of GPP.

This new February episode of the Skin of Color Savvy podcast highlights why 2026 may be the year of skin health equity in the dermatology field.

FDA approves dupilumab for allergic fungal rhinosinusitis, supported by phase 3 LIBERTY-AFRS-AIMS data showing reduced symptoms and corticosteroid or surgery use.

HCPLive speaks with Mark Lebwohl, MD, about recent data on those with psoriasis and obesity or overweight treated with ixekizumab (Taltz) and tirzepatide (Zepbound).